Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders
The benefits of combination antiretroviral therapy (ART) for HIV cognitive disorders vary substantially between individuals. This study evaluated whether cerebrospinal fluid (CSF) drug penetration and CSF virological suppression influence the extent of neuropsychological (NP) improvement during ART....
Gespeichert in:
| Veröffentlicht in: | Annals of neurology 2004-09, Vol.56 (3), p.416-423 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 423 |
|---|---|
| container_issue | 3 |
| container_start_page | 416 |
| container_title | Annals of neurology |
| container_volume | 56 |
| creator | Letendre, Scott L. McCutchan, J. Allen Childers, Meredith E. Woods, Steven P. Lazzaretto, Deborah Heaton, Robert K. Grant, Igor Ellis, Ronald J. |
| description | The benefits of combination antiretroviral therapy (ART) for HIV cognitive disorders vary substantially between individuals. This study evaluated whether cerebrospinal fluid (CSF) drug penetration and CSF virological suppression influence the extent of neuropsychological (NP) improvement during ART. Overall performance on a battery of NP tests administered at baseline and follow‐up (median 15 weeks) was computed by using the global deficit score (GDS) methods in 31 cognitively impaired, HIV‐infected individuals who began new ART regimens. Virological suppression (attaining undetectable viral load by RT‐PCR at follow‐up) was assessed separately for plasma and CSF. Subjects on regimens containing greater numbers of CSF‐penetrating drugs showed significantly greater reduction in CSF viral load. Subjects attaining CSF virological suppression demonstrated greater GDS improvement than those who did not (median GDS change, 0.62 vs 0.23; p = 0.01). A similar trend for plasma did not reach statistical significance (p = 0.053). NP improvement was greater in ART‐naive versus treatment‐experienced subjects. In a multivariate model (overall p = 0.0008), significant, independent predictors of GDS reduction were CSF HIV RNA suppression, baseline antiretroviral history, and their interaction. Including CSF‐penetrating drugs in the ART regimen and monitoring CSF viral load may be indicated for individuals with HIV‐associated cognitive impairment Ann Neurol 2004. |
| doi_str_mv | 10.1002/ana.20198 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66851363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17514393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5218-50fdac3a77d31d129e4cd29beddf37a8633e9fe98a53e30e0372808ffa0e66663</originalsourceid><addsrcrecordid>eNqF0E1v1DAQBmALgehSOPAHUC4gcUhrx7FjH1ellI9q4dCKozW1x11D4ix2Uth_j5dd6Anhy1yeeUd-CXnO6AmjtDmFCCcNZVo9IAsmOKtV0-qHZEG5bGvBeHtEnuT8lVKqJaOPyVFBrVZSL8j1eVxDtCHeVhCnkHBK411I0FfTGhNstpUfU7WeB4hVGIY5jg59sAGj3VYFzrmy420MU7jDyoU8JocpPyWPPPQZnx3mMbl-e3519q6-_HTx_mx5WVvRMFUL6h1YDl3nOHOs0dha1-gbdM7zDpTkHLVHrUBw5BQp7xpFlfdAUZbHj8mrfe4mjd9nzJMZQrbY9xBxnLORUpXvl5j_QdYJ1nK9g6_30KYx54TebFIYIG0No2ZXtillm99lF_viEDrfDOju5aHdAl4eAGQLvU-7pvO9k4wJRUVxp3v3I_S4_fdFs1wt_5yu9xshT_jz7wakb0Z2vBPmy-rCfLzi9M3nD9ys-C-_LaYg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17514393</pqid></control><display><type>article</type><title>Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Letendre, Scott L. ; McCutchan, J. Allen ; Childers, Meredith E. ; Woods, Steven P. ; Lazzaretto, Deborah ; Heaton, Robert K. ; Grant, Igor ; Ellis, Ronald J.</creator><creatorcontrib>Letendre, Scott L. ; McCutchan, J. Allen ; Childers, Meredith E. ; Woods, Steven P. ; Lazzaretto, Deborah ; Heaton, Robert K. ; Grant, Igor ; Ellis, Ronald J. ; HNRC Group ; the HNRC Group</creatorcontrib><description>The benefits of combination antiretroviral therapy (ART) for HIV cognitive disorders vary substantially between individuals. This study evaluated whether cerebrospinal fluid (CSF) drug penetration and CSF virological suppression influence the extent of neuropsychological (NP) improvement during ART. Overall performance on a battery of NP tests administered at baseline and follow‐up (median 15 weeks) was computed by using the global deficit score (GDS) methods in 31 cognitively impaired, HIV‐infected individuals who began new ART regimens. Virological suppression (attaining undetectable viral load by RT‐PCR at follow‐up) was assessed separately for plasma and CSF. Subjects on regimens containing greater numbers of CSF‐penetrating drugs showed significantly greater reduction in CSF viral load. Subjects attaining CSF virological suppression demonstrated greater GDS improvement than those who did not (median GDS change, 0.62 vs 0.23; p = 0.01). A similar trend for plasma did not reach statistical significance (p = 0.053). NP improvement was greater in ART‐naive versus treatment‐experienced subjects. In a multivariate model (overall p = 0.0008), significant, independent predictors of GDS reduction were CSF HIV RNA suppression, baseline antiretroviral history, and their interaction. Including CSF‐penetrating drugs in the ART regimen and monitoring CSF viral load may be indicated for individuals with HIV‐associated cognitive impairment Ann Neurol 2004.</description><identifier>ISSN: 0364-5134</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.20198</identifier><identifier>PMID: 15349869</identifier><identifier>CODEN: ANNED3</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Anti-Retroviral Agents - pharmacology ; Anti-Retroviral Agents - therapeutic use ; Biological and medical sciences ; Chi-Square Distribution ; Cognition Disorders - cerebrospinal fluid ; Cognition Disorders - drug therapy ; Cognition Disorders - psychology ; Female ; HIV Infections - drug therapy ; HIV Infections - psychology ; HIV-1 - drug effects ; HIV-1 - metabolism ; Human immunodeficiency virus ; Humans ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neurology ; Neuropsychological Tests - statistics & numerical data ; Prospective Studies ; Statistics, Nonparametric</subject><ispartof>Annals of neurology, 2004-09, Vol.56 (3), p.416-423</ispartof><rights>Copyright © 2003 American Neurological Association</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5218-50fdac3a77d31d129e4cd29beddf37a8633e9fe98a53e30e0372808ffa0e66663</citedby><cites>FETCH-LOGICAL-c5218-50fdac3a77d31d129e4cd29beddf37a8633e9fe98a53e30e0372808ffa0e66663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fana.20198$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fana.20198$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16115805$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15349869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Letendre, Scott L.</creatorcontrib><creatorcontrib>McCutchan, J. Allen</creatorcontrib><creatorcontrib>Childers, Meredith E.</creatorcontrib><creatorcontrib>Woods, Steven P.</creatorcontrib><creatorcontrib>Lazzaretto, Deborah</creatorcontrib><creatorcontrib>Heaton, Robert K.</creatorcontrib><creatorcontrib>Grant, Igor</creatorcontrib><creatorcontrib>Ellis, Ronald J.</creatorcontrib><creatorcontrib>HNRC Group</creatorcontrib><creatorcontrib>the HNRC Group</creatorcontrib><title>Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>The benefits of combination antiretroviral therapy (ART) for HIV cognitive disorders vary substantially between individuals. This study evaluated whether cerebrospinal fluid (CSF) drug penetration and CSF virological suppression influence the extent of neuropsychological (NP) improvement during ART. Overall performance on a battery of NP tests administered at baseline and follow‐up (median 15 weeks) was computed by using the global deficit score (GDS) methods in 31 cognitively impaired, HIV‐infected individuals who began new ART regimens. Virological suppression (attaining undetectable viral load by RT‐PCR at follow‐up) was assessed separately for plasma and CSF. Subjects on regimens containing greater numbers of CSF‐penetrating drugs showed significantly greater reduction in CSF viral load. Subjects attaining CSF virological suppression demonstrated greater GDS improvement than those who did not (median GDS change, 0.62 vs 0.23; p = 0.01). A similar trend for plasma did not reach statistical significance (p = 0.053). NP improvement was greater in ART‐naive versus treatment‐experienced subjects. In a multivariate model (overall p = 0.0008), significant, independent predictors of GDS reduction were CSF HIV RNA suppression, baseline antiretroviral history, and their interaction. Including CSF‐penetrating drugs in the ART regimen and monitoring CSF viral load may be indicated for individuals with HIV‐associated cognitive impairment Ann Neurol 2004.</description><subject>Adult</subject><subject>Anti-Retroviral Agents - pharmacology</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chi-Square Distribution</subject><subject>Cognition Disorders - cerebrospinal fluid</subject><subject>Cognition Disorders - drug therapy</subject><subject>Cognition Disorders - psychology</subject><subject>Female</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - psychology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - metabolism</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neurology</subject><subject>Neuropsychological Tests - statistics & numerical data</subject><subject>Prospective Studies</subject><subject>Statistics, Nonparametric</subject><issn>0364-5134</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0E1v1DAQBmALgehSOPAHUC4gcUhrx7FjH1ellI9q4dCKozW1x11D4ix2Uth_j5dd6Anhy1yeeUd-CXnO6AmjtDmFCCcNZVo9IAsmOKtV0-qHZEG5bGvBeHtEnuT8lVKqJaOPyVFBrVZSL8j1eVxDtCHeVhCnkHBK411I0FfTGhNstpUfU7WeB4hVGIY5jg59sAGj3VYFzrmy420MU7jDyoU8JocpPyWPPPQZnx3mMbl-e3519q6-_HTx_mx5WVvRMFUL6h1YDl3nOHOs0dha1-gbdM7zDpTkHLVHrUBw5BQp7xpFlfdAUZbHj8mrfe4mjd9nzJMZQrbY9xBxnLORUpXvl5j_QdYJ1nK9g6_30KYx54TebFIYIG0No2ZXtillm99lF_viEDrfDOju5aHdAl4eAGQLvU-7pvO9k4wJRUVxp3v3I_S4_fdFs1wt_5yu9xshT_jz7wakb0Z2vBPmy-rCfLzi9M3nD9ys-C-_LaYg</recordid><startdate>200409</startdate><enddate>200409</enddate><creator>Letendre, Scott L.</creator><creator>McCutchan, J. Allen</creator><creator>Childers, Meredith E.</creator><creator>Woods, Steven P.</creator><creator>Lazzaretto, Deborah</creator><creator>Heaton, Robert K.</creator><creator>Grant, Igor</creator><creator>Ellis, Ronald J.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Willey-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200409</creationdate><title>Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders</title><author>Letendre, Scott L. ; McCutchan, J. Allen ; Childers, Meredith E. ; Woods, Steven P. ; Lazzaretto, Deborah ; Heaton, Robert K. ; Grant, Igor ; Ellis, Ronald J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5218-50fdac3a77d31d129e4cd29beddf37a8633e9fe98a53e30e0372808ffa0e66663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Anti-Retroviral Agents - pharmacology</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chi-Square Distribution</topic><topic>Cognition Disorders - cerebrospinal fluid</topic><topic>Cognition Disorders - drug therapy</topic><topic>Cognition Disorders - psychology</topic><topic>Female</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - psychology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - metabolism</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neurology</topic><topic>Neuropsychological Tests - statistics & numerical data</topic><topic>Prospective Studies</topic><topic>Statistics, Nonparametric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Letendre, Scott L.</creatorcontrib><creatorcontrib>McCutchan, J. Allen</creatorcontrib><creatorcontrib>Childers, Meredith E.</creatorcontrib><creatorcontrib>Woods, Steven P.</creatorcontrib><creatorcontrib>Lazzaretto, Deborah</creatorcontrib><creatorcontrib>Heaton, Robert K.</creatorcontrib><creatorcontrib>Grant, Igor</creatorcontrib><creatorcontrib>Ellis, Ronald J.</creatorcontrib><creatorcontrib>HNRC Group</creatorcontrib><creatorcontrib>the HNRC Group</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Letendre, Scott L.</au><au>McCutchan, J. Allen</au><au>Childers, Meredith E.</au><au>Woods, Steven P.</au><au>Lazzaretto, Deborah</au><au>Heaton, Robert K.</au><au>Grant, Igor</au><au>Ellis, Ronald J.</au><aucorp>HNRC Group</aucorp><aucorp>the HNRC Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>2004-09</date><risdate>2004</risdate><volume>56</volume><issue>3</issue><spage>416</spage><epage>423</epage><pages>416-423</pages><issn>0364-5134</issn><eissn>1531-8249</eissn><coden>ANNED3</coden><abstract>The benefits of combination antiretroviral therapy (ART) for HIV cognitive disorders vary substantially between individuals. This study evaluated whether cerebrospinal fluid (CSF) drug penetration and CSF virological suppression influence the extent of neuropsychological (NP) improvement during ART. Overall performance on a battery of NP tests administered at baseline and follow‐up (median 15 weeks) was computed by using the global deficit score (GDS) methods in 31 cognitively impaired, HIV‐infected individuals who began new ART regimens. Virological suppression (attaining undetectable viral load by RT‐PCR at follow‐up) was assessed separately for plasma and CSF. Subjects on regimens containing greater numbers of CSF‐penetrating drugs showed significantly greater reduction in CSF viral load. Subjects attaining CSF virological suppression demonstrated greater GDS improvement than those who did not (median GDS change, 0.62 vs 0.23; p = 0.01). A similar trend for plasma did not reach statistical significance (p = 0.053). NP improvement was greater in ART‐naive versus treatment‐experienced subjects. In a multivariate model (overall p = 0.0008), significant, independent predictors of GDS reduction were CSF HIV RNA suppression, baseline antiretroviral history, and their interaction. Including CSF‐penetrating drugs in the ART regimen and monitoring CSF viral load may be indicated for individuals with HIV‐associated cognitive impairment Ann Neurol 2004.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>15349869</pmid><doi>10.1002/ana.20198</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0364-5134 |
| ispartof | Annals of neurology, 2004-09, Vol.56 (3), p.416-423 |
| issn | 0364-5134 1531-8249 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66851363 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Anti-Retroviral Agents - pharmacology Anti-Retroviral Agents - therapeutic use Biological and medical sciences Chi-Square Distribution Cognition Disorders - cerebrospinal fluid Cognition Disorders - drug therapy Cognition Disorders - psychology Female HIV Infections - drug therapy HIV Infections - psychology HIV-1 - drug effects HIV-1 - metabolism Human immunodeficiency virus Humans Male Medical sciences Middle Aged Multivariate Analysis Neurology Neuropsychological Tests - statistics & numerical data Prospective Studies Statistics, Nonparametric |
| title | Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T17%3A10%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhancing%20antiretroviral%20therapy%20for%20human%20immunodeficiency%20virus%20cognitive%20disorders&rft.jtitle=Annals%20of%20neurology&rft.au=Letendre,%20Scott%20L.&rft.aucorp=HNRC%20Group&rft.date=2004-09&rft.volume=56&rft.issue=3&rft.spage=416&rft.epage=423&rft.pages=416-423&rft.issn=0364-5134&rft.eissn=1531-8249&rft.coden=ANNED3&rft_id=info:doi/10.1002/ana.20198&rft_dat=%3Cproquest_cross%3E17514393%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17514393&rft_id=info:pmid/15349869&rfr_iscdi=true |